Orchestra BioMed Holdings, Inc.
OBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.20 | 0.18 | -0.00 | -0.08 |
| FCF Yield | -34.52% | -15.23% | -19.98% | -9.56% |
| EV / EBITDA | -2.20 | -5.36 | -4.37 | -9.34 |
| Quality | ||||
| ROIC | -105.30% | -60.84% | -41.65% | -663.19% |
| Gross Margin | 92.27% | 93.26% | 90.89% | 125.45% |
| Cash Conversion Ratio | 0.83 | 0.94 | 0.87 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -9.28% | – | -14.75% | – |
| Free Cash Flow Growth | -10.05% | -54.64% | -51.65% | 26.27% |
| Safety | ||||
| Net Debt / EBITDA | 0.09 | 0.56 | 0.24 | 0.20 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -23.52 |
| Efficiency | ||||
| Inventory Turnover | 1.18 | 1.27 | 1.17 | 2.93 |
| Cash Conversion Cycle | -8,863.57 | -5,391.26 | -4,175.11 | -3,653.29 |